Sandra C. Patterson - 10 Jun 2024 Form 4 Insider Report for GILEAD SCIENCES, INC. (GILD)

Source evidence Original filing metadata and source links for verification. 5 source fields
SEC form
4
Accepted by SEC
11 Jun 2024, 19:23:09 UTC
Prior SEC filing
12 Mar 2024
Next SEC filing
12 Aug 2024
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ Edward S. Son by Power of Attorney for Sandra C. Patterson

Key filing fact

Sandra C. Patterson filed Form 4 for GILEAD SCIENCES, INC. (GILD) on 11 Jun 2024.

Key facts

  • This page summarizes Sandra C. Patterson's Form 4 filing for GILEAD SCIENCES, INC. (GILD).
  • 3 reported transactions and 1 derivative row are listed below.
  • Accepted by SEC: 11 Jun 2024, 19:23.

Change

  • Previous filing in this sequence was filed on 12 Mar 2024.
  • Current net transaction value: -$16,639.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

GILD transaction

Common Stock

Options Exercise

Transaction value
Shares
+901
Change %
+2.8%
Price
Shares after
33,533
Date
10 Jun 2024
Ownership
Direct
Footnotes
F1
GILD transaction

Common Stock

Tax liability

Transaction value
$16,639
Shares
-255
Change %
-0.76%
Price
$65.25
Shares after
33,278
Date
10 Jun 2024
Ownership
Direct

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

GILD transaction Derivative

Restricted Stock Unit

Options Exercise

Transaction value
Shares
-901
Change %
-4.8%
Price
Shares after
17,762
Date
10 Jun 2024
Ownership
Direct
Underlying class
Common Stock
Underlying amount
901
Exercise price
Footnotes
F1, F2
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.

Footnote F2

The restricted stock units have a four year vesting schedule. 25% vest on the first anniversary of the date of grant. The balance will vest 6.25% quarterly thereafter until fully vested.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .